Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

被引：5

作者：

van Hellemond, Irene E. G. ^{[1
]}

Smorenburg, Carolien H. ^{[2
]}

Peer, Petronella G. M. ^{[3
]}

Swinkels, Astrid C. P. ^{[4
]}

Seynaeve, Caroline M. ^{[5
]}

van der Sangen, Maurice J. C. ^{[6
]}

Kroep, Judith R. ^{[7
]}

de Graaf, Hiltje ^{[8
]}

Honkoop, Aafke H. ^{[9
]}

Erdkamp, Frans L. G. ^{[10
]}

van den Berkmortel, Franchette W. P. J. ^{[11
]}

de Roos, Wilfred K. ^{[12
]}

Linn, Sabine C. ^{[13
]}

Imholz, Alexander L. T. ^{[14
]}

de Boer, Maaike ^{[1
]}

Tjan-Heijnen, Vivianne C. G. ^{[1
,15
]}

机构：

[1] Maastricht Univ, Med Ctr, Dept Med Oncol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands

[2] Med Ctr Alkmaar, Dept Internal Med, Alkmaar, Netherlands

[3] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Biostat, Med Ctr, Nijmegen, Netherlands

[4] Netherlands Comprehens Canc Org IKNL, Dept Clin Res, Utrecht, Netherlands

[5] Erasmus MC, Dept Med Oncol, Inst Canc, Rotterdam, Netherlands

[6] Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands

[7] Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands

[8] Med Ctr Leeuwarden, Dept Med Oncol, Leeuwarden, Netherlands

[9] Isala Clin, Dept Med Oncol, Zwolle, Netherlands

[10] Zuyderland Med Ctr, Dept Med Oncol, Sittard, Netherlands

[11] Zuyderland Med Ctr, Dept Med Oncol, Heerlen, Netherlands

[12] Gelderse Vallei Hosp, Dept Surg, Ede, Netherlands

[13] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[14] Deventer Hosp, Dept Med Oncol, Deventer, Netherlands

[15] Maastricht Univ, Med Ctr, Div Med Oncol, Dept Internal Med, POB 5800, NL-6202 AZ Maastricht, Netherlands

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 180卷 / 03期

关键词：

Breast cancer; Tamoxifen; Aromatase inhibitor; Bone health; Osteoporosis; Bisphosphonates; Survival; Bone metastases; Distant recurrence-free survival; ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; IN-VITRO; THERAPY; CELLS; RISK; CHEMOTHERAPY; METASTASIS; MECHANISMS; CLODRONATE;

D O I：

10.1007/s10549-020-05567-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2-3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS), and evaluated the effect of bisphosphonates on DRFS. Methods We selected all patients with a BMD measurement within 3 years after randomisation (landmark) without any DRFS events. Kaplan-Meier methods and Cox proportional hazards models were used for analyses. Results Of 1860 eligible patients, 1142 had a DEXA scan before the landmark. The BMD was normal in 436 (38.2%) and showed osteopenia in 565 (49.5%) and osteoporosis in 141 (12.3%) patients. After a median follow-up of 5.0 years from the landmark, neither osteopenia nor osteoporosis (compared with normal BMD) were associated with DRFS in both the 6-year [osteopenia HR 0.82 (95% CI 0.45-1.49), osteoporosis HR 1.10 (95% CI 0.26-4.67)] and the 3-year arm [osteopenia HR 0.75 (95% CI 0.40-1.42), osteoporosis HR 1.86 (95% CI 0.43-8.01)]. Moreover, bisphosphonate use did not impact DRFS. Conclusion No association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.

引用

页码：675 / 685

页数：11

共 33 条

[1] Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database [J].

Agarwal, Parul ;

Moshier, Erin ;

Ru, Meng ;

Ohri, Nisha ;

Ennis, Ronald ;

Rosenzweig, Kenneth ;

Mazumdar, Madhu .

CANCER CONTROL, 2018, 25 (01)

[2] Osteoporosis treatment and 10 years' oestrogen receptor plus breast cancer outcome in postmenopausal women treated with aromatase inhibitors [J].

Bouvard, B. ;

Chatelais, J. ;

Soulie, P. ;

Hoppe, E. ;

Saulnier, P. ;

Capitain, O. ;

Mege, M. ;

Mesgouez-Nebout, N. ;

Jadaud, E. ;

Abadie-Lacourtoisie, S. ;

Campone, M. ;

Legrand, E. .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :87-94

[3] Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial [J].

Brown, Janet ;

Rathbone, Emma ;

Hinsley, Samantha ;

Gregory, Walter ;

Gossiel, Fatma ;

Marshall, Helen ;

Burkinshaw, Roger ;

Shulver, Helen ;

Thandar, Hasina ;

Bertelli, Gianfilippo ;

Maccon, Keane ;

Bowman, Angela ;

Hanby, Andrew ;

Bell, Richard ;

Cameron, David ;

Coleman, Robert .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (08) :871-879

[4] Final 5-year results of Z-FAST trial [J].

Brufsky, Adam M. ;

Harker, W. Graydon ;

Beck, J. Thaddeus ;

Bosserman, Linda ;

Vogel, Charles ;

Seidler, Christopher ;

Jin, Lixian ;

Warsi, Ghulam ;

Argonza-Aviles, Eliza ;

Hohneker, John ;

Ericson, Solveig G. ;

Perez, Edith A. .

CANCER, 2012, 118 (05) :1192-1201

[5] Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status [J].

Chen, Hsiu-Man ;

Chen, Fang-Ping ;

Yang, Kang-Chung ;

Yuan, Shin-Sheng .

JAMA NETWORK OPEN, 2019, 2 (03)

[6] Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women [J].

Chlebowski, Rowan T. ;

Chen, Zhao ;

Cauley, Jane A. ;

Anderson, Garnet ;

Rodabough, Rebecca J. ;

McTiernan, Anne ;

Lane, Dorothy S. ;

Manson, JoAnn E. ;

Snetselaar, Linda ;

Yasmeen, Shagufta ;

O'Sullivan, Mary Jo ;

Safford, Monika ;

Hendrix, Susan L. ;

Wallace, Robert B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3582-3590

[7] Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J].

Coleman, R. ;

Powles, T. ;

Paterson, A. ;

Gnant, M. ;

Anderson, S. ;

Diel, I. ;

Gralow, J. ;

von Minckwitz, G. ;

Moebus, V. ;

Bergh, J. ;

Pritchard, K. I. ;

Bliss, J. ;

Cameron, D. ;

Evans, V. ;

Pan, H. ;

Peto, R. ;

Bradley, R. ;

Gray, R. ;

Bartsch, R. ;

Dubsky, P. ;

Fesl, C. ;

Fohler, H. ;

Greil, R. ;

Jakesz, R. ;

Lang, A. ;

Luschin-Ebengreuth, G. ;

Marth, C. ;

Mlineritsch, B. ;

Samonigg, H. ;

Singer, C. F. ;

Steger, G. G. ;

Stoeger, H. ;

Olivotto, I. ;

Ragaz, J. ;

Christiansen, P. ;

Ejlertsen, B. ;

Ewertz, M. ;

Jensen, M-B ;

Moller, S. ;

Mouridsen, H. T. ;

Eiermann, W. ;

Hilfrich, J. ;

Jonat, W. ;

Kaufmann, M. ;

Kreienberg, R. ;

Schumacher, M. ;

Blohmer, J. U. ;

Costa, S. D. ;

Eidtmann, H. ;

Gerber, B. .

LANCET, 2015, 386 (10001) :1353-1361

[8] Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results [J].

Coleman, R. ;

de Boer, R. ;

Eidtmann, H. ;

Llombart, A. ;

Davidson, N. ;

Neven, P. ;

von Minckwitz, G. ;

Sleeboom, H. P. ;

Forbes, J. ;

Barrios, C. ;

Frassoldati, A. ;

Campbell, I. ;

Paija, O. ;

Martin, N. ;

Modi, A. ;

Bundred, N. .

ANNALS OF ONCOLOGY, 2013, 24 (02) :398-405

[9] Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial [J].

Coleman, Robert ;

Cameron, David ;

Dodwell, David ;

Bell, Richard ;

Wilson, Caroline ;

Rathbone, Emma ;

Keane, Maccon ;

Gil, Miguel ;

Burkinshaw, Roger ;

Grieve, Robert ;

Barrett-Lee, Peter ;

Ritchie, Diana ;

Liversedge, Victoria ;

Hinsley, Samantha ;

Marshall, Helen .

LANCET ONCOLOGY, 2014, 15 (09) :997-1006

[10] Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. [J].

Coleman, Robert E. ;

Finkelstein, Dianne ;

Barrios, Carlos H. ;

Martin, Miguel ;

Iwata, Hiroji ;

Glaspy, John A. ;

Zhou, Ying ;

Jandial, Danielle ;

Chan, Arlene .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 →